mTOR Inhibition and the Tumor Vasculature

Author(s): Anne Dormond-Meuwly, Marc Dufour, Nicolas Demartines, Olivier Dormond

Journal Name: Current Angiogenesis (Discontinued)

Volume 1 , Issue 1 , 2012


Blocking tumor growth by targeting the tumor vasculature is a promising approach in cancer therapy. Both, disrupting tumor vessels as well as normalization of tumor vessel abnormalities have shown anti-cancer efficacy. A plethora of agents that act on the tumor vasculature have been developed; however, so far few have shown clinical benefits. Among the successful agents, inhibitors of the mammalian target of rapamycin (mTOR) are able to reduce tumor growth by targeting tumor vessels. mTOR inhibition exerts at least three different effects on the tumor vasculature. First, it reduces tumor angiogenesis. Second it normalizes the tumor vasculature and third, it promotes the formation of thrombosis in tumor vessels. The characterization of the molecular functions regulated by mTOR and of relevance to the tumor vasculature is therefore important in order to further identify biological mechanisms involved in the tumor vascular network as well as to improve the efficacy of these inhibitors. Here, we will first enumerate the evidences for the anti-angiogenic activities of mTOR inhibitors and describe the molecular mechanisms involved. We will further analyze the effects of mTOR inhibition on vascular normalization and also describe how mTOR inhibition promotes thrombosis formation specifically in tumor vessels. Finally, we will describe a new generation of mTOR inhibitors and examine their effects on the tumor vasculature.

Keywords: Angiogenesis, cancer, endothelial cell, mTOR, proliferation, rapamycin, signaling

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 29 March, 2012
Page: [11 - 19]
Pages: 9
DOI: 10.2174/2211552811201010011

Article Metrics

PDF: 28